Press Release Oncology Venture is issuing 2,255,639 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP

NEXT STORY
New Data Suggest Men May Want Non-Drug Alternatives For Treatment of Enlarged Prostate Symptoms
PREV STORY
3B Future Health Fund announces new investment in iOnctura
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Apricus Biosciences Announces Closing of $3.55 Million Public Offering

author_avatar
NASDAQ Market News

Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)

Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive ...

author_avatar
NASDAQ Market News

Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference

author_avatar
NASDAQ Market News